Androxal Vs. Testosterone Gel Head-To-Head Trials Get FDA Pumped
Executive Summary
After meeting with the agency, Repros Therapeutics expects that two studies comparing its oral product against testosterone gel will accentuate Androxal’s safety advantages.
You may also be interested in...
Repros Low-Testosterone Therapy NDA May Be Delayed Until 4Q 2014
The company is preparing two head-to-head studies against approved testosterone replacement therapies to try to demonstrate Androxal’s superiority, even as apparent data fraud at a study site may alter the final analysis of a pivotal Phase III study.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.